Nuvation Bio Receives FDA Approval for Updated Treatment Duration of IBTROZI® for ROS1-Positive Lung Cancer

Nuvation Bio Celebrates FDA Approval for IBTROZI®

Nuvation Bio Inc., a pioneering force in oncology, has made headlines with the recent approval from the U.S. Food and Drug Administration (FDA) for a supplemental New Drug Application (sNDA) concerning their innovative treatment, IBTROZI® (taletrectinib). This achievement comes just four months ahead of the anticipated PDUFA (Prescription Drug User Fee Act) date, marking a significant milestone in the battle against non-small cell lung cancer (NSCLC) characterized by ROS1 positivity.

The updated label of IBTROZI now includes insights from the TRUST-I study, reflecting a remarkable median duration of response (DOR) of approximately 49.7 months in TKI-naïve patients. This duration signifies over four years of consistent clinical benefit, underscoring the long-term efficacy and safety profile of IBTROZI for patients facing this challenging diagnosis.

The background of this approval stems from an extensive patient follow-up period, amounting to 51 months, which incorporated new data from both the pivotal TRUST-I and TRUST-II studies conducted till August 2025. The studies emphasized that many participants remained on therapy for extended periods while reporting sustained responses. Such data was not only key to the approval but was also presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 and published in the reputable Journal of Clinical Oncology.

Dr. David Hung, the Founder and CEO of Nuvation Bio, articulated the significance of this approval, stating, "A median duration of response exceeding four years—the longest reported for any FDA-approved ROS1 TKI—is an extraordinary result for patients living with ROS1+ NSCLC. It also empowers physicians with concrete evidence to prescribe IBTROZI at crucial stages of patient care." This approval provides both physicians and patients a clearer understanding of treatment expectations amid the uncertainty that often accompanies a cancer diagnosis.

IBTROZI was granted full approval by the FDA back in June 2025 for the treatment of both locally advanced and metastatic ROS1+ NSCLC. In addition to its U.S. approval, IBTROZI has also gained traction in international markets, being recognized in Japan and China. The European Medicines Agency and the UK’s Medicines and Healthcare products Regulatory Agency have also validated Marketing Authorisation Applications for broader authorization assessments.

The relevance of ROS1+ NSCLC cannot be overstated; over one million individuals worldwide are diagnosed with this form of lung cancer every year, with an estimated 2% having ROS1-positive tumors. Alarmingly, about 35% of newly diagnosed metastatic ROS1+ NSCLC patients present with brain metastases, which is also the most common area for disease progression.

IBTROZI, a next-generation ROS1 inhibitor, offers an oral, potent solution that actively targets these challenging tumors, holding promise for improving patient outcomes. Its FDA approval for advanced ROS1+ NSCLC aligns with Nuvation Bio’s commitment to addressing the pressing challenges in cancer treatment.

As a company founded in 2018 by industry veteran Dr. David Hung, Nuvation Bio continues to push forward with innovative treatments, including the ongoing evaluation of IBTROZI through the TRUST clinical program, which encompasses multiple studies dedicated to understanding and enhancing the drug's efficacy and safety.

The recent developments at Nuvation Bio highlight a promising direction in lung cancer treatment, aiming to provide improved quality of life and better care for patients battling ROS1+ NSCLC. Through continued research and FDA engagements, the company plans to solidify its position as a leader in oncology innovations.

For more information about IBTROZI and its application in treating ROS1+ NSCLC, visit www.IBTROZI.com.